Phone Number

Clinical Research
(803) 935-8300
Institutional Review Board
(803) 935-8300
Nursing Education
(803) 935-8504
Professional Training
(803) 936-7215
Graduate Medical Education Family Medicine
(803) 739-3491
Graduate Medical Education Transitional Year
(803) 791-2769

Cancer Research

Working Toward a Cure

Our researchers contribute to the South Carolina Central Cancer Registry and have partnered with the MUSC Hollings Cancer Center to stay up-to-date on the latest clinical trials and treatments.

Current Trials

Bladder Cancer

Cysview

Description

The purpose of the study is to gather more information on the current use of Blue Light Cystoscopy with Cysview® in urologists' practices. This trial is a registry study for patients with bladder cancer who undergo cystoscopy. Cysview is an FDA approved drug imaging agent that is absorbed by malignant cells causing them to appear pink under blue light thus making them easier to see.

Open to enrollment

Posted By: Dr. T. Brian Willard

Posted Date: 5/20/2022

Location: Lexington Urology

Breast Cancer

WF-2202

Description
Optimizing Psychosocial Intervention for Breast Cancer-related Sexual Morbidity: The Sexual Health and Intimacy Education (SHINE) Trial

Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors. 

Open to enrollment. 

Posted By: Dr. Steven Madden

Posted Date: 5/24/2024

Location: Lexington Medical Cancer Center

NRG-CC011

Description
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Double-Blinded Controlled Trial.

A study to examine computerized training to improve concentration, learning new things, and remembering in breast cancer survivors. 

Open to enrollment. 

Posted By: Dr. Steven Madden

Posted Date: 5/23/2024

Location: Lexington Medical Cancer Center

NRG-BR008 HERO

Description
A Phase III Randomized Trial of Radiotherapy Optimization for low-risk HER2-Positive Breast Cancer.

This trial compares the recurrence-free interval (RFI) among patients with early stage, low-risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the current standard of care. 

Open to enrollment.

Posted By: Dr. Quillin Davis

Posted Date: 4/12/2024

Location: Lexington Medical Cancer Center

S2212 SCARLET

Description
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study

This phase III trial compares the effects of shorter chemotherapy-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.

Open to enrollment.

Posted By: Dr. Steven Madden

Posted Date: 8/28/2023

Location: Lexington Medical Cancer Center

A012103

Description
Pembrolizumab vs. observation in people with triple-negative breast cancer who had a pathologic complete response after chemotherapy plus pembrolizumab.

Open to enrollment. 

Posted By: Dr. Steven Madden

Posted Date: 7/28/2023

Location: Lexington Medical Cancer Center

A212102

Description
Blinded Reference Set for Multicancer Early Detection Blood Tests. In this study, blood samples will be collected from patients with and without cancer to evaluate tests for early cancer detection.

Open to enrollment.

Posted By: Dr. James Wells

Posted Date: 6/23/2023

Location: Lexington Medical Cancer Center

SERENA-6

Description
This study is intended to show the superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib or abemaciclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.

Open to enrollment.

Posted By: Dr. Steven Madden

Posted Date: 11/2/2022

Location: Lexington Medical Cancer Center

A011801

Description
The Compassher2 Trials (Comprehensive Use Of Pathologic Response Assessment To Optimize Therapy In Her2-Positive Breast Cancer): Compassher2 Residual Disease (Rd), A Double-Blinded, Phase Iii Randomized Trial Of T-Dm1 And Placebo Compared With T-Dm1 And Tucatinib.

This trial studies how well trastuzumab emtanzine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. Giving T-DMI and tucatinib together may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone. 

Open to enrollment 

Posted By: Dr. Steven Madden

Posted Date: 9/27/2019

Location: Lexington Medical Cancer Center

MA.39 Tailor RT

Description
This study tests regional radiation therapy in patients with low risk breast cancer.

Posted By: Dr. Davis

Posted Date: 9/5/2019

Location: Lexington Medical Cancer Center

Gastrointestinal Cancer

A022104 The Janus Rectal Cancer Trial

Description
A randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer.

Testing the addition of an anti-cancer drug, irinotecan, to the standard chemotherapy treatment (FOLFOX) after long-course radiation therapy for advanced-stage rectal cancers to improve the rate of complete response and long-term rates of organ preservation and continuing response. 

Open to enrollment.

Posted By: Dr. James Wells

Posted Date: 4/24/2024

Location: Lexington Medical Cancer Center

Head & Neck Cancer

Lung Cancer

Alchemist - 081801

Description
Testing the addition of a type of drug called immunotherapy to the usual chemotherapy treatment for non-small cell lung cancer.

Open to enrollment

Posted By: Dr. James Wells

Posted Date: 9/30/2022

Location: Lexington Medical Cancer Center

Emerge 402

Description
This is an observational study to identify and measure the effects of a medication called Zepzelca in a real-world setting in Adult Patients with Extensive Stage Small Cell Lung Cancer (SCLC).

Open to enrollment

Posted By: Dr. Steven Madden

Posted Date: 11/1/2021

Location: Lexington Medical Cancer Center

Alchemist - A151216

Description
Genetic Testing For Patients with Resectable or Resected Lung Cancer

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial 

Open to enrollment 

Posted By: Dr. James Wells

Posted Date: 3/15/2015

Location: Lexington Medical Cancer Center

Prostate Cancer

BRAT

Description
The purpose of the Prostate BRAchyTherapy (BRAT) Registry is to measure clinical outcomes of patients treated with Brachytherapy at Lexington Medical Center (LMC).

Open to enrollment

Posted By: Dr. Quillin Davis

Posted Date: 11/1/2021

Location: Lexington Medical Cancer Center

EA8184

Description
To Evaluate if Green Tea can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring.

This study is being done to answer the following question:  Can we lower the chance of your prostate cancer growing by adding Sunphenon® 90D (containing green tea catechins) by closely monitoring your prostate cancer?

Open to enrollment

Posted By: Dr. T. Brian Willard

Posted Date: 11/1/2021

Location: Lexington Urology